49 research outputs found
A demonstration of within-subjects latent inhibition in the human: limitations and advantages
Abstract The magnitude of latent inhibition (LI) (a retardation of associative learning due to prior exposure to the conditioning stimulus) was measured in healthy volunteers using both a within-and a between-subjects version of the task. Reliable LI was demonstrated for the within-subjects paradigm (using a design that fully counter-balanced stimulus of pre-exposure) but the magnitude of the effect was smaller than for the between-subjects version. Measures of schizotypal personality were found to be associated with reduced LI for the between-subjects task, but not for the within-subjects task. We hypothesised that for the within-subjects task learning about the first stimulus-consequence association (usually that for the not pre-exposed (NPE) stimulus) primes learning about the second stimulus, thus reducing the effect of pre-exposure and restricting the range of LI scores. In turn, this restricted range of LI scores does not allow subtle differences on schizotypal personality dimensions to reveal their effect using this withinsubjects paradigm. In conclusion, a within-subjects LI task has been developed which is not open to explanation in terms of differences in stimulus salience. However, the limited range of pre-exposure scores in the current within-subject paradigm may severely limit it is use as an indicator of subtle performance changes.
International network of cancer genome projects
The International Cancer Genome Consortium (ICGC) was launched to coordinate large-scale cancer genome studies in tumors from 50 different cancer types and/or subtypes that are of clinical and societal importance across the globe. Systematic studies of over 25,000 cancer genomes at the genomic, epigenomic, and transcriptomic levels will reveal the repertoire of oncogenic mutations, uncover traces of the mutagenic influences, define clinically-relevant subtypes for prognosis and therapeutic management, and enable the development of new cancer therapies
Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial.
BACKGROUND: Staphylococcus aureus bacteraemia is a common cause of severe community-acquired and hospital-acquired infection worldwide. We tested the hypothesis that adjunctive rifampicin would reduce bacteriologically confirmed treatment failure or disease recurrence, or death, by enhancing early S aureus killing, sterilising infected foci and blood faster, and reducing risks of dissemination and metastatic infection. METHODS: In this multicentre, randomised, double-blind, placebo-controlled trial, adults (≥18 years) with S aureus bacteraemia who had received ≤96 h of active antibiotic therapy were recruited from 29 UK hospitals. Patients were randomly assigned (1:1) via a computer-generated sequential randomisation list to receive 2 weeks of adjunctive rifampicin (600 mg or 900 mg per day according to weight, oral or intravenous) versus identical placebo, together with standard antibiotic therapy. Randomisation was stratified by centre. Patients, investigators, and those caring for the patients were masked to group allocation. The primary outcome was time to bacteriologically confirmed treatment failure or disease recurrence, or death (all-cause), from randomisation to 12 weeks, adjudicated by an independent review committee masked to the treatment. Analysis was intention to treat. This trial was registered, number ISRCTN37666216, and is closed to new participants. FINDINGS: Between Dec 10, 2012, and Oct 25, 2016, 758 eligible participants were randomly assigned: 370 to rifampicin and 388 to placebo. 485 (64%) participants had community-acquired S aureus infections, and 132 (17%) had nosocomial S aureus infections. 47 (6%) had meticillin-resistant infections. 301 (40%) participants had an initial deep infection focus. Standard antibiotics were given for 29 (IQR 18-45) days; 619 (82%) participants received flucloxacillin. By week 12, 62 (17%) of participants who received rifampicin versus 71 (18%) who received placebo experienced treatment failure or disease recurrence, or died (absolute risk difference -1·4%, 95% CI -7·0 to 4·3; hazard ratio 0·96, 0·68-1·35, p=0·81). From randomisation to 12 weeks, no evidence of differences in serious (p=0·17) or grade 3-4 (p=0·36) adverse events were observed; however, 63 (17%) participants in the rifampicin group versus 39 (10%) in the placebo group had antibiotic or trial drug-modifying adverse events (p=0·004), and 24 (6%) versus six (2%) had drug interactions (p=0·0005). INTERPRETATION: Adjunctive rifampicin provided no overall benefit over standard antibiotic therapy in adults with S aureus bacteraemia. FUNDING: UK National Institute for Health Research Health Technology Assessment
Effects of fluoxetine on functional outcomes after acute stroke (FOCUS): a pragmatic, double-blind, randomised, controlled trial
Background
Results of small trials indicate that fluoxetine might improve functional outcomes after stroke. The FOCUS trial aimed to provide a precise estimate of these effects.
Methods
FOCUS was a pragmatic, multicentre, parallel group, double-blind, randomised, placebo-controlled trial done at 103 hospitals in the UK. Patients were eligible if they were aged 18 years or older, had a clinical stroke diagnosis, were enrolled and randomly assigned between 2 days and 15 days after onset, and had focal neurological deficits. Patients were randomly allocated fluoxetine 20 mg or matching placebo orally once daily for 6 months via a web-based system by use of a minimisation algorithm. The primary outcome was functional status, measured with the modified Rankin Scale (mRS), at 6 months. Patients, carers, health-care staff, and the trial team were masked to treatment allocation. Functional status was assessed at 6 months and 12 months after randomisation. Patients were analysed according to their treatment allocation. This trial is registered with the ISRCTN registry, number ISRCTN83290762.
Findings
Between Sept 10, 2012, and March 31, 2017, 3127 patients were recruited. 1564 patients were allocated fluoxetine and 1563 allocated placebo. mRS data at 6 months were available for 1553 (99·3%) patients in each treatment group. The distribution across mRS categories at 6 months was similar in the fluoxetine and placebo groups (common odds ratio adjusted for minimisation variables 0·951 [95% CI 0·839–1·079]; p=0·439). Patients allocated fluoxetine were less likely than those allocated placebo to develop new depression by 6 months (210 [13·43%] patients vs 269 [17·21%]; difference 3·78% [95% CI 1·26–6·30]; p=0·0033), but they had more bone fractures (45 [2·88%] vs 23 [1·47%]; difference 1·41% [95% CI 0·38–2·43]; p=0·0070). There were no significant differences in any other event at 6 or 12 months.
Interpretation
Fluoxetine 20 mg given daily for 6 months after acute stroke does not seem to improve functional outcomes. Although the treatment reduced the occurrence of depression, it increased the frequency of bone fractures. These results do not support the routine use of fluoxetine either for the prevention of post-stroke depression or to promote recovery of function.
Funding
UK Stroke Association and NIHR Health Technology Assessment Programme
Clinical Applications of Behaviour Modification Techniques with Long Stay Psychiatric Patients. Departments of Psychology and Psychiatry, University of Leeds, and Stanley Royd Hospital, Wakefield.
Learning Theory Approaches to Psychiatry. John C. Boulougouris (Ed.), Chichester: John Wiley, 1982, pp. xxi + 262, £24.00.
Schizophrenia. J. S. Strauss and W. T. CarpenterJr, New York: Plenum, 1981, pp. xi+220, $22.50.
Les croyances délirantes
This paper presents a cognitive model of delusion formation. It draws upon studies of the schizophrenia syndrome which emphasize a disturbance in the integration of current sensory input with stored material. It is argued that delusional beliefs are multidimensional and that both anormal perceptual experiences and altered reasoning style may play a crucial role in their development.Der Artikel stellt ein Modell der Herausbildung und Fortführung des Deliriums vor, wobei die Leitidee die einer Gesamtheit von psychologischen Faktoren ist, die die finale Manifestation delirierender Überzeugungen beeinflussen. Der Autor unterstreicht die Rolle anomaler Prozesse in der Perzeption und bei der Urteilsbildung sowie die eigentümlichen Transformationen in der Art und Weise, wie sinnlich empfangene Daten umgesetzt und in den bereits vorhandenen Informationsbestand integriert werden